Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginNet MarginOperating MarginReturn on Sales

Cogent Biosciences (COGT) EBIT Margin (2017 - 2020)

Cogent Biosciences has reported EBIT Margin over the past 4 years, most recently at 18333.01% for Q3 2020.

  • Quarterly results put EBIT Margin at 18333.01% for Q3 2020, down 1715301.0% from a year ago — trailing twelve months through Jun 2021 was 31649.68% (down 3155189.0% YoY), and the annual figure for FY2025 was 10887.1%, changed.
  • EBIT Margin for Q3 2020 was 18333.01% at Cogent Biosciences, down from 1402.08% in the prior quarter.
  • Over the last five years, EBIT Margin for COGT hit a ceiling of 14.65% in Q4 2019 and a floor of 18333.01% in Q3 2020.
  • Median EBIT Margin over the past 4 years was 332.18% (2017), compared with a mean of 1640.08%.
  • Peak annual rise in EBIT Margin hit 30051bps in 2020, while the deepest fall reached -1715301bps in 2020.
  • Cogent Biosciences' EBIT Margin stood at 324.07% in 2017, then increased by 27bps to 236.64% in 2018, then surged by 106bps to 14.65% in 2019, then plummeted by -125223bps to 18333.01% in 2020.
  • The last three reported values for EBIT Margin were 18333.01% (Q3 2020), 1402.08% (Q2 2020), and 87.34% (Q1 2020) per Business Quant data.